Member Info for TRENCH123

Somebody bought 362280 shares @ 0.7439 at 15.16 and sold them again @ 0.7299 at 16.27

I would have thought a sell is more probable

I agree. We had delayed contracts from June 2024 which gave us a head start into the new financial year but we really need to capitalise on this momentum by converting further chunks of our pipeline in the near term

For anyone who has not watched it, I suggest you take a look at the Peter Sargent interview with Proactive

PS is oozing confidence and if things turn out anywhere near the outlook he projects then PYC shareholders are looking to some very interesting times ahead

Pete Sargent attending 4th December

https://www.genesisconference.com/

The excellent positive interview which Pete Sargent gave two weeks ago has attracted around 600 views on YouTube and there is clearly interest in PYC at the present time

It is important that PYC build on this interest by releasing some decent news via RNS in the near term. Maybe then we will see some lasting improvement in share price

In February 2024 PYC were granted a contract to support the University of Sheffield in innovative research on an insect model of cancer treatment using the Drosophila fly, with the PYC work scheduled to start in the second half of the year

The attached extract from the UK Research and Innovation site shows the studies as still 'Active' and with funding due to finish this month

https://gtr.ukri.org/projects?ref=NC%2FW001136%2F1

It will be interesting to learn of progress made in the study and also whether it is to be extended with potential further involvement of PYC

The presence of PYC at various key trade events over the last couple of months should result in new business. Let's hope for some contract announcements before too long

I note that PYC are involved in the Bio Europe Digital Partnering 12/13 November

7.776 million shares traded = 3.84% of shares in issue and highest daily volume for three months

Use of our dosing tool(s) in NHS setting would be nice

Definitely worth a listen

Includes PS comments 'We are making some great progress with our personalised dosing tool .. with one of our partners based in the US, a company called DoseMe, to try and get the tool accessible to clinicians primarily in the US but also across Europe'

The DoseMe customer base extends beyond the US. This is an extract from an announcement made earlier this year with specific reference to Europe : -

"We are thrilled to have successfully navigated the transition to the MDR framework," said Paul Edwards, CEO, DoseMe. "This achievement not only demonstrates our commitment to regulatory excellence but also ensures that our customers and their patients remain protected under the latest European medical device regulations. Our team has worked diligently to meet these requirements, and we are proud to continue providing a safe and compliant solution"

https://doseme-rx.com/en-gb/news-media/article/dosemerx-ce-certificate-for-mdr-onformity

PS bought 459090 shares at 8.38am yesterday morning

Just wondering if 521534 shares traded at 8.00am could be further purchase by him ?

AGM is 19th November

Positive day for all holders with excellent appointment

Recently issued report picked up through PYC Linkedin :-

https://www.einpresswire.com/article/754466873/biosimulation-market-segments-drivers-restraints-and-trends-for-2024-2033

Hopefully some good opportunities for PYC to expand its business

Issued just a few days ago :-

https://www.miltonpark.co.uk/occupier-news/new-occupiers-create-hive-of-activity-at-bee-house/

Can only be a positive attending such conferences IMO

Whilst the PARTNER study paper is the main presentation it is likely that the progression of this to the active and more exciting PREDICT-ONC trial will also be a subject of conversation at the conference

Not sure what the obsession is with Laura. Give it a rest please guys

DeBull, good to see Tim Corn posting positively

It is Thursday number 240